COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.

Clinical Pharmacology and Therapeutics
G. W. StrohbehnPankti D Reid

Abstract

Interleukin-6 (IL-6)-mediated hyperinflammation may contribute to the mortality of coronavirus disease 2019 (COVID-19). The IL-6 receptor-blocking monoclonal antibody tocilizumab has been repurposed for COVID-19, but prospective trials and dose-finding studies in COVID-19 have not yet fully reported. We conducted a single-arm phase II trial of low-dose tocilizumab in nonintubated hospitalized adult patients with COVID-19, radiographic pulmonary infiltrate, fever, and C-reactive protein (CRP) ≥ 40 mg/L. We hypothesized that doses significantly lower than the emerging standards of 400 mg or 8 mg/kg would resolve clinical and laboratory indicators of hyperinflammation. A dose range from 40 to 200 mg was evaluated, with allowance for one repeat dose at 24 to 48 hours. The primary objective was to assess the relationship of dose to fever resolution and CRP response. Thirty-two patients received low-dose tocilizumab, with the majority experiencing fever resolution (75%) and CRP decline consistent with IL-6 pathway abrogation (86%) in the 24-48 hours following drug administration. There was no evidence of a relationship between dose and fever resolution or CRP decline over the dose range of 40-200 mg. Within the 28-day follow-up, 5 (1...Continue Reading

References

Feb 1, 1988·The Journal of Experimental Medicine·A MuraguchiT Kishimoto
Jul 27, 2017·The New England Journal of Medicine·John H StoneNeil Collinson
Jul 4, 2018·Proceedings of the National Academy of Sciences of the United States of America·Hsin-Ying HuangSanjiv A Luther
Jun 21, 2019·JAMA Oncology·Mark J RatainAllen S Lichter
Mar 21, 2020·Lancet·Puja MehtaUNKNOWN HLH Across Speciality Collaboration, UK
Apr 17, 2020·Clinical Pharmacology and Therapeutics·Anthony V SerritellaMark J Ratain
May 1, 2020·Proceedings of the National Academy of Sciences of the United States of America·Xiaoling XuHaiming Wei
May 5, 2020·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Hasan K Siddiqi, Mandeep R Mehra
May 24, 2020·The New England Journal of Medicine·John H BeigelUNKNOWN ACTT-1 Study Group Members
May 28, 2020·The New England Journal of Medicine·Jason D GoldmanUNKNOWN GS-US-540-5773 Investigators
Jun 4, 2020·Clinical Pharmacology and Therapeutics·Garth W StrohbehnMark J Ratain
Jul 9, 2020·Nature·Elizabeth J WilliamsonBen Goldacre
Jul 12, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Emily C SomersJason M Pogue
Aug 25, 2020·The Lancet Rheumatology·Giovanni GuaraldiCristina Mussini
Sep 3, 2020·JAMA : the Journal of the American Medical Association·Hallie C Prescott, Todd W Rice
Sep 3, 2020·JAMA : the Journal of the American Medical Association·UNKNOWN WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working GroupJohn C Marshall
Oct 21, 2020·JAMA Internal Medicine·Jonathan B Parr
Oct 21, 2020·JAMA Internal Medicine·Shruti GuptaUNKNOWN STOP-COVID Investigators
Oct 21, 2020·JAMA Internal Medicine·Olivier HermineUNKNOWN CORIMUNO-19 Collaborative Group
Oct 22, 2020·The New England Journal of Medicine·John H StoneUNKNOWN BACC Bay Tocilizumab Trial Investigators

❮ Previous
Next ❯

Citations

Apr 8, 2021·Expert Review of Clinical Immunology·Soheila RezaeiReza Mosaed
May 22, 2021·Intensive Care Medicine·Timothy Arthur Chandos SnowNishkantha Arulkumaran
Jul 9, 2021·Signal Transduction and Targeted Therapy·Lan YangYufeng Zhou
Sep 2, 2021·IUBMB Life·Hiu Yan LamKwang Seok Ahn

❮ Previous
Next ❯

Datasets Mentioned

BETA
GM007019

Methods Mentioned

BETA
coronary artery bypass

Clinical Trials Mentioned

NCT04331795

Software Mentioned

COVIDOSE
COVACTA
Stata
REMDACTA
EMPACTA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

MedRxiv : the Preprint Server for Health Sciences
G. W. StrohbehnPankti D Reid
MedRxiv : the Preprint Server for Health Sciences
G. W. StrohbehnPankti D Reid
The New England Journal of Medicine
David E LeafWei Wang
JAMA Internal Medicine
Chengliang Yang, Mingyao Liu
JAMA Internal Medicine
Jean-François RossiBernard Klein
© 2021 Meta ULC. All rights reserved